These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

467 related articles for article (PubMed ID: 17078853)

  • 1. DHE in the pharmacotherapy of migraine: potential for a larger role.
    Saper JR; Silberstein S; Dodick D; Rapoport A
    Headache; 2006 Nov; 46 Suppl 4():S212-20. PubMed ID: 17078853
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dosing and administration of ergotamine tartrate and dihydroergotamine.
    Mathew NT
    Headache; 1997; 37 Suppl 1():S26-32. PubMed ID: 9009471
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Appropriate use of ergotamine tartrate and dihydroergotamine in the treatment of migraine: current perspectives.
    Young WB
    Headache; 1997; 37 Suppl 1():S42-5. PubMed ID: 9009473
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Orally inhaled dihydroergotamine: a review.
    Tepper SJ
    Headache; 2013 Sep; 53 Suppl 2():43-53. PubMed ID: 24024602
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Symptomatic and prophylactic treatment of migraine and tension-type headache.
    Schulman EA; Silberstein SD
    Neurology; 1992 Mar; 42(3 Suppl 2):16-21. PubMed ID: 1557187
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Where is dihydroergotamine mesylate in the changing landscape of migraine therapy?
    Morren JA; Galvez-Jimenez N
    Expert Opin Pharmacother; 2010 Dec; 11(18):3085-93. PubMed ID: 21080856
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ergotamine tartrate and dihydroergotamine mesylate: safety profiles.
    Lipton RB
    Headache; 1997; 37 Suppl 1():S33-41. PubMed ID: 9009472
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dihydroergotamine: role in the treatment of migraine.
    Schürks M
    Expert Opin Drug Metab Toxicol; 2009 Sep; 5(9):1141-8. PubMed ID: 19624283
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dihydroergotamine for early and late treatment of migraine with cutaneous allodynia: an open-label pilot trial.
    Silberstein SD; Young WB; Hopkins MM; Gebeline-Myers C; Bradley KC
    Headache; 2007 Jun; 47(6):878-85. PubMed ID: 17578539
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Pharmacologic treatment of acute migraine attack in children].
    Cuvellier JC; Joriot S; Auvin S; Vallée L
    Arch Pediatr; 2005 Mar; 12(3):316-25. PubMed ID: 15734131
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relatively slow and long-lasting antimigraine effect of dihydroergotamine is most likely due to basic pharmacological attributes of the drug: a review.
    Tfelt-Hansen PC
    Cephalalgia; 2013 Oct; 33(13):1122-31. PubMed ID: 23588793
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rescue therapy for acute migraine, part 1: triptans, dihydroergotamine, and magnesium.
    Kelley NE; Tepper DE
    Headache; 2012 Jan; 52(1):114-28. PubMed ID: 22211870
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dihydroergotamine: a review of its use in the treatment of migraine and other headaches.
    Scott AK
    Clin Neuropharmacol; 1992 Aug; 15(4):289-96. PubMed ID: 1516074
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dihydroergotamine: a review of formulation approaches for the acute treatment of migraine.
    Silberstein SD; Kori SH
    CNS Drugs; 2013 May; 27(5):385-94. PubMed ID: 23620146
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Implementation of an Intravenous Dihydroergotamine Protocol for Refractory Migraine in Children.
    Theroux LM; Cappa R; Mendoza A; Mallawaarachchi I; Samanta D; Goodkin HP
    Headache; 2020 Sep; 60(8):1653-1663. PubMed ID: 32853454
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized, double blind, placebo-controlled study of MAP0004 in adult patients with migraine.
    Aurora SK; Rozen TD; Kori SH; Shrewsbury SB
    Headache; 2009 Jun; 49(6):826-37. PubMed ID: 19545249
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nasal delivery of antimigraine drugs: clinical rationale and evidence base.
    Rapoport A; Winner P
    Headache; 2006 Nov; 46 Suppl 4():S192-201. PubMed ID: 17078851
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnosis and symptomatic treatment of migraine.
    Saper JR
    Headache; 1997; 37 Suppl 1():S1-14. PubMed ID: 9009469
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Central sensitization theory of migraine: clinical implications.
    Dodick D; Silberstein S
    Headache; 2006 Nov; 46 Suppl 4():S182-91. PubMed ID: 17078850
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Migraine: dihydroergotamine nasal spray--an alternative].
    Beubler E
    Wien Med Wochenschr; 1995; 145(14):326-31. PubMed ID: 7483646
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.